MOTIF BIO PLC/S (NASDAQ:MTFB) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of MOTIF BIO PLC/S (NASDAQ:MTFB) from a sell rating to a hold rating in a research note released on Tuesday, Zacks.com reports.

According to Zacks, “Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company’s product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK. “

Separately, Northland Securities set a $5.00 target price on shares of MOTIF BIO PLC/S and gave the stock a buy rating in a research note on Monday, July 15th.

NASDAQ MTFB traded down $0.03 on Tuesday, hitting $0.60. The company had a trading volume of 663 shares, compared to its average volume of 74,610. The stock has a market capitalization of $9.22 million, a P/E ratio of -8.59 and a beta of 0.08. The company’s fifty day moving average price is $0.70. MOTIF BIO PLC/S has a 12-month low of $0.60 and a 12-month high of $11.50.

An institutional investor recently bought a new position in MOTIF BIO PLC/S stock. Virtu Financial LLC bought a new position in shares of MOTIF BIO PLC/S (NASDAQ:MTFB) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,865 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned about 0.13% of MOTIF BIO PLC/S as of its most recent SEC filing. 7.58% of the stock is currently owned by institutional investors.

MOTIF BIO PLC/S Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Read More: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on MOTIF BIO PLC/S (MTFB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.